Biomerica Reports Fiscal 2025 Year End Results

• $1.3 Million in Operating Expense Reductions Achieved– Operating Loss Improves 19% Year-Over-Year
• Resilient Portfolio Performance with International Sales Despite Global Economic Uncertainties
• Cash Used in Operating Activities Reduced to $3.8 Million vs. $5.3 Million in the Prior Year, Reflecting Stronger Operating Discipline

IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) — Biomerica, Inc. (NASDAQ:BMRA) today reported its financial results for the fiscal year ended May 31, 2025 (Fiscal 2025).

The Company reported net sales of $5.3 million, compared to $5.4 million in the prior year. Revenue was modestly lower due to global tariff-related uncertainties, which caused certain international customers to delay orders, and a shift in product mix with fewer over-the-counter (OTC) retail sales during the fourth quarter. These headwinds were partially offset with increased sales from inFoods^® IBS.

Gross profit for the year was $498,000, versus $611,000 in the prior year, reflecting the impact of the macro-economic events on revenue and product mix.

Cash used in operating activities improved significantly to $3.8 million, compared to $5.3 million in the prior year, a $1.5 million improvement driven by operating efficiencies and disciplined expense management.

Through disciplined cost management, Biomerica reduced selling, general and administrative expenses to $4.6 million, compared to $5.5 million in the prior year and reduced research and development expenses to $1.0 million, compared to $1.5 million in the prior year. In total, operating expenses declined by more than $1.3 million, delivering on the cost-reduction goals announced at the beginning of the fiscal year.

As a result, operating loss improved to $5.1 million, compared to $6.4 million in the prior year – a 19% year-over-year improvement, despite revenue headwinds.